SABS
SAB Biotherapeutics, Inc. NASDAQ Listed Feb 9, 2021$4.09
Mkt Cap $39.1M
52w Low $1.60
49.8% of range
52w High $6.60
50d MA $3.86
200d MA $3.29
P/E (TTM)
15.8x
EV/EBITDA
4.1x
P/B
0.4x
Debt/Equity
0.0x
ROE
8.8%
P/FCF
-1.6x
RSI (14)
—
ATR (14)
—
Beta
0.61
50d MA
$3.86
200d MA
$3.29
Avg Volume
553.4K
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
2100 East 54th Street North · Sioux Falls, SD 57104 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.16 | -0.46 | -187.5% | 3.84 | +5.5% | +6.8% | +19.3% | +19.5% | +8.1% | +2.6% | — |
| Nov 14, 2025 | AMC | -0.59 | -0.21 | +64.4% | 3.24 | +0.0% | +8.0% | +20.7% | +18.2% | +17.3% | +21.9% | — |
| Aug 7, 2025 | AMC | -0.82 | -1.09 | -32.9% | 2.23 | -1.8% | -1.3% | -9.4% | -3.1% | -3.6% | -0.9% | — |
| May 9, 2025 | AMC | -1.00 | -0.56 | +44.0% | 1.79 | +0.0% | +10.6% | +5.0% | +3.4% | +8.4% | +3.4% | — |
| Mar 28, 2025 | AMC | -1.16 | -1.23 | -6.0% | 1.48 | +0.0% | -8.1% | -16.9% | -15.5% | -20.3% | -23.6% | — |
| Nov 6, 2024 | AMC | -1.07 | -1.12 | -4.7% | 3.95 | +0.0% | -17.2% | -11.1% | -19.2% | -13.4% | -17.5% | — |
| Aug 8, 2024 | AMC | -1.13 | -0.79 | +30.1% | 2.71 | -4.1% | -12.9% | -13.3% | -15.1% | -18.5% | -17.0% | — |
| May 20, 2024 | AMC | -0.98 | -0.54 | +44.9% | 3.45 | -13.0% | -15.7% | -17.7% | -24.9% | -21.2% | -21.2% | — |
| Apr 1, 2024 | AMC | -0.62 | -3.38 | -445.2% | 4.29 | +10.0% | +4.9% | +4.0% | +3.0% | +1.2% | +4.0% | — |
| Nov 13, 2023 | AMC | -1.00 | -1.00 | +0.0% | 9.30 | +0.0% | -2.2% | -2.2% | -3.2% | -8.7% | -10.3% | — |
| Aug 21, 2023 | AMC | -1.60 | -1.40 | +12.5% | 7.90 | -4.9% | -4.1% | -3.8% | -8.9% | -15.2% | -23.0% | — |
| May 16, 2023 | AMC | -0.80 | -1.50 | -87.5% | 7.80 | +9.1% | +9.1% | +9.6% | +9.4% | +15.4% | +13.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | Chardan Capital | Maintains | Buy → Buy | — | $4.10 | $4.26 | +3.9% | +11.7% | +12.0% | +1.2% | -3.9% | -0.7% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.84 | $4.05 | +5.5% | +6.8% | +19.3% | +19.5% | +8.1% | +2.6% |
| Dec 18 | Chardan Capital | Maintains | Buy → Buy | — | $3.96 | $3.98 | +0.5% | -0.3% | +0.8% | -3.0% | -3.0% | -3.0% |
| Nov 17 | Chardan Capital | Maintains | Buy → Buy | — | $3.24 | $3.24 | +0.0% | +8.0% | +20.7% | +18.2% | +17.3% | +21.9% |
| Sep 19 | Chardan Capital | Maintains | Buy → Buy | — | $2.79 | $2.80 | +0.4% | -11.5% | -11.1% | -19.0% | -22.6% | -24.7% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $2.23 | $2.19 | -1.8% | -1.3% | -9.4% | -3.1% | -3.6% | -0.9% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.70 | $2.57 | -4.8% | -3.3% | -7.8% | -3.7% | -5.6% | -6.3% |
| May 15 | Chardan Capital | Maintains | Buy → Buy | — | $1.85 | $1.91 | +3.2% | +4.9% | +0.0% | -2.7% | -0.5% | -7.6% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.36 | $1.38 | +1.5% | -9.6% | -8.1% | -13.2% | -16.9% | -18.4% |
| Apr 1 | Chardan Capital | Maintains | Buy → Buy | — | $1.36 | $1.38 | +1.5% | -9.6% | -8.1% | -13.2% | -16.9% | -18.4% |
| Jan 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.07 | $2.08 | +0.5% | +7.7% | +4.8% | +5.8% | +3.9% | +7.7% |
| Jan 29 | Chardan Capital | Maintains | Buy → Buy | — | $2.07 | $2.08 | +0.5% | +7.7% | +4.8% | +5.8% | +3.9% | +7.7% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $3.95 | $3.95 | +0.0% | -17.2% | -11.1% | -19.2% | -13.4% | -17.5% |
| Sep 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.80 | $2.82 | +0.7% | -1.1% | -0.4% | -3.6% | -1.1% | -8.6% |
| Sep 9 | Chardan Capital | Maintains | Buy → Buy | — | $2.84 | $2.81 | -1.1% | +2.5% | -3.2% | -1.4% | -2.5% | -1.8% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.36 | $2.42 | +2.5% | -0.4% | -2.5% | -6.4% | -4.7% | +2.5% |
| Aug 12 | Chardan Capital | Maintains | Buy → Buy | — | $2.36 | $2.42 | +2.5% | -0.4% | -2.5% | -6.4% | -4.7% | +2.5% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.45 | $3.00 | -13.0% | -15.7% | -17.7% | -24.9% | -21.2% | -21.2% |
| May 21 | Chardan Capital | Maintains | Buy → Buy | — | $3.45 | $3.00 | -13.0% | -15.7% | -17.7% | -24.9% | -21.2% | -21.2% |
| Apr 16 | Chardan Capital | Maintains | Buy → Buy | — | $4.61 | $4.94 | +7.2% | +5.9% | -0.2% | -3.3% | -6.9% | -4.8% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.61 | $4.94 | +7.2% | +5.9% | -0.2% | -3.3% | -6.9% | -4.8% |
| Apr 2 | Chardan Capital | Maintains | Buy → Buy | — | $4.29 | $4.72 | +10.0% | +4.9% | +4.0% | +3.0% | +1.2% | +4.0% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.29 | $4.72 | +10.0% | +4.9% | +4.0% | +3.0% | +1.2% | +4.0% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.82 | $6.00 | +3.1% | +4.1% | +2.1% | +1.4% | +6.9% | +2.7% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.30 | $9.30 | +0.0% | -2.2% | -2.2% | -3.2% | -8.7% | -10.3% |
| Oct 4 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $6.70 | $6.88 | +2.6% | +5.8% | +1.7% | -1.5% | +5.7% | +11.9% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.70 | $9.13 | +5.0% | +1.1% | -1.3% | -1.4% | -6.9% | -13.8% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.05 | $9.00 | -0.6% | -3.9% | -2.8% | -5.1% | -5.2% | -10.5% |
| Jun 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.77 | $9.00 | +2.7% | +3.2% | -0.8% | +0.4% | -2.0% | -2.2% |
| Jun 15 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $8.77 | $9.00 | +2.7% | +3.2% | -0.8% | +0.4% | -2.0% | -2.2% |
| Jun 14 | Chardan Capital | Maintains | Buy → Buy | — | $8.75 | $8.75 | +0.0% | +0.2% | +3.4% | -0.6% | +0.6% | -1.8% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.80 | $8.70 | -1.1% | -11.4% | -3.3% | -2.8% | -3.0% | +2.3% |
| Apr 27 | Chardan Capital | Maintains | Buy → Buy | — | $7.21 | $7.50 | +4.0% | +24.7% | +24.5% | +22.0% | +16.0% | +20.6% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.80 | $6.90 | +81.6% | +99.7% | +90.9% | +102.6% | +186.8% | +155.2% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $5.00 | +13.6% | +5.7% | +10.0% | +0.0% | -6.7% | -6.6% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.50 | $11.30 | +7.6% | +1.9% | +2.9% | -1.0% | +7.6% | +1.9% |
| Aug 10 | Chardan Capital | Maintains | Buy → Buy | — | $11.50 | $11.70 | +1.7% | -2.6% | -2.6% | -2.6% | +4.3% | +0.9% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $18.00 | $17.50 | -2.8% | -0.6% | +10.6% | +7.8% | +11.1% | +11.7% |
| Mar 31 | Chardan Capital | Maintains | Buy → Buy | — | $26.00 | $26.00 | +0.0% | +44.6% | +33.1% | +25.4% | +8.1% | +1.9% |
| Nov 5 | Chardan Capital | Maintains | Buy → Buy | — | $80.70 | $84.50 | +4.7% | +3.3% | +4.2% | +21.3% | +12.5% | +16.1% |
| Nov 2 | Baird | Maintains | Outperform → Outperform | — | $84.30 | $104.98 | +24.5% | +8.8% | +0.0% | -4.3% | -1.1% | -0.2% |
No insider trades available.
8-K · 7.01
! Medium
SAB Biotherapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
SAB Biotherapeutics disclosed Phase 1 clinical trial data for SAB-142, its human anti-thymocyte biologic, representing progress in its first-in-human study pipeline.
Apr 22
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
SABS secured $69.7 million in underwriting support from Jefferies, likely signaling an upcoming equity offering that could dilute existing shareholders but provides capital for growth or debt reduction.
Mar 19
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
SAB-142's Phase 1 data showing C-peptide preservation in Type 1 diabetes patients validates its mechanism and could support higher valuations if Phase 2 trials succeed, warranting close monitoring for upcoming trial milestones.
Mar 10
Data updated apr 26, 2026 11:58pm
· Source: massive.com